1.105
0.45%
0.00
Rapt Therapeutics Inc stock is traded at $1.105, with a volume of 1.04M.
It is up +0.45% in the last 24 hours and down -37.99% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$1.105
Open:
$1.19
24h Volume:
1.04M
Relative Volume:
2.20
Market Cap:
$37.41M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-0.4108
EPS:
-2.69
Net Cash Flow:
$-98.17M
1W Performance:
-36.57%
1M Performance:
-37.99%
6M Performance:
-72.52%
1Y Performance:
-92.15%
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
RAPT | 1.10 | 37.41M | 3.25M | -116.80M | -98.17M | -2.69 |
VRTX | 467.34 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 761.42 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 564.61 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.62 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.69 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
Feb-22-24 | Downgrade | UBS | Buy → Neutral |
Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Feb-16-24 | Initiated | Evercore ISI | Outperform |
Feb-15-24 | Initiated | Wolfe Research | Outperform |
Sep-14-23 | Initiated | Berenberg | Buy |
Aug-09-23 | Initiated | Stifel | Buy |
Jun-15-23 | Initiated | Barclays | Overweight |
Jan-04-23 | Initiated | Guggenheim | Buy |
Dec-01-22 | Initiated | Goldman | Buy |
Sep-21-22 | Initiated | CapitalOne | Overweight |
May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
Dec-09-21 | Initiated | JP Morgan | Overweight |
Aug-12-21 | Initiated | SVB Leerink | Outperform |
Jun-21-21 | Initiated | Piper Sandler | Overweight |
Jun-01-20 | Initiated | H.C. Wainwright | Buy |
May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
Apr-13-20 | Initiated | ROTH Capital | Buy |
Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
Nov-25-19 | Initiated | UBS | Buy |
Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
RAPT Therapeutics announces option repricing to retain talent By Investing.com - Investing.com Nigeria
Leerink Partnrs Issues Optimistic Forecast for RAPT Earnings - MarketBeat
Leerink Partnrs Expects Lower Earnings for RAPT Therapeutics - MarketBeat
RAPT Therapeutics' SWOT analysis: biotech firm faces challenges, seeks new path - Investing.com Canada
RAPT Therapeutics Reports Improved Q3 2024 Results - TipRanks
RAPT Therapeutics' (RAPT) Hold Rating Reaffirmed at Stifel Nicolaus - MarketBeat
Wells Fargo & Company Has Lowered Expectations for RAPT Therapeutics (NASDAQ:RAPT) Stock Price - MarketBeat
RAPT Therapeutics (NASDAQ:RAPT) Earns "Neutral" Rating from HC Wainwright - MarketBeat
RAPT Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire
RAPT Therapeutics Narrows Q3 Loss by 41%, Cuts R&D Spend Amid Restructuring | RAPT Stock News - StockTitan
RAPT Therapeutics stock hits 52-week low at $1.49 By Investing.com - Investing.com Australia
RAPT Therapeutics Inc (RAPT) Quarterly 10-Q Report - Quartzy
RAPT Therapeutics stock hits 52-week low at $1.49 - Investing.com
Rapt Scraps Zelnecirnon, But Not Giving Up On CCR4 - Citeline News & Insights
Crude Oil Down 3%; Aramark Posts Upbeat Earnings - Benzinga
Nasdaq Moves Lower; Canaan Shares Surge - Benzinga
JPMorgan cuts Rapt Therapeutics to Underweight By Investing.com - Investing.com UK
JPMorgan Chase & Co. Downgrades RAPT Therapeutics (NASDAQ:RAPT) to Underweight - MarketBeat
U.S. Stock market: Binah Capital Group(+105.01%) and CERo Therapeutics(+152.00%) see strong gains, RAPT Therapeutics(−44.12%) declines during mid day trading - Business Upturn
RAPT scraps zelnecirnon program, stock plunges 46% (update) - Seeking Alpha
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - Clinical Trials Arena
Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury - Benzinga
U.S. Stock market: RAPT Therapeutics drops 41% while CERo Therapeutics surges 136% in early trading - Business Upturn
Dow Jumps Over 400 Points; Monday.com Shares Fall After Q3 Results - Benzinga
Rapt Therapeutics Stops Development of Asthma, Atopic Dermatitis Drug Candidate After Reaction Sidelines Trials - MarketWatch
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury - The Manila Times
Based on Recent FDA Feedback RAPT Therapeutics Stops - GlobeNewswire
RAPT Therapeutics Halts Key Drug Program After FDA Safety Concerns, Liver Injury | RAPT Stock News - StockTitan
Contrasting RAPT Therapeutics (NASDAQ:RAPT) and Elanco Animal Health (NYSE:ELAN) - Defense World
Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth? - Simply Wall St
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky - Yahoo Finance
Vanguard Group Inc's Strategic Acquisition in RAPT Therapeutics Inc - GuruFocus.com
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings? - MSN
RAPT Therapeutics stock plunges to 52-week low of $1.65 By Investing.com - Investing.com Australia
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by Analysts - MarketBeat
RAPT Therapeutics stock plunges to 52-week low of $1.65 - Investing.com
RAPT stock touches 52-week low at $1.72 amid sharp yearly decline - Investing.com
Point72 Asset Management L.P. Acquires 706,900 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
RAPT Therapeutics Inc (RAPT) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Cubist Systematic Strategies LLC Increases Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
XTX Topco Ltd Invests $108,000 in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
RAPT Therapeutics' SWOT analysis: biotech stock faces clinical hurdles - Investing.com
RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now - Yahoo Finance
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability - Insider Monkey
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers - Insider Monkey
RAPT stock touches 52-week low at $1.76 amid sharp annual decline - Investing.com India
Daily Progress: RAPT Therapeutics Inc (RAPT) Drop -7.25, Closing at 1.79 - The Dwinnex
Federated Hermes Inc. Boosts Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
Acadian Asset Management LLC Raises Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - MarketBeat
RAPT Therapeutics (NASDAQ:RAPT) Price Target Cut to $2.00 by Analysts at UBS Group - Defense World
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rapt Therapeutics Inc Stock (RAPT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Brockstedt Dirk G. | Chief Scientific Officer |
Dec 29 '23 |
Option Exercise |
6.18 |
8,000 |
49,440 |
27,070 |
HO WILLIAM | Chief Medical Officer |
Dec 21 '23 |
Sale |
21.68 |
2,500 |
54,200 |
15,020 |
HO WILLIAM | Chief Medical Officer |
Nov 28 '23 |
Sale |
13.72 |
1,500 |
20,580 |
17,520 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):